ROLE OF INTRANASAL STEROIDAL SPRAY IN SEASONAL ALLERGIC RHINITIS WITH OCULAR SYMPTOMS
Vineel Muppidi1, Lingaiah Jadi2, Kalicheti Prabhakar Reddy3, Sudeep Madisetti4, Anvesh Krishna Med5, Madasani Anunya Reddy6

1Professor, Department of ENT, Chalmeda Anand Rao Institute of Medical Sciences, Bommakal, Karimnagar, Telangana.
2Associate Professor, Department of ENT, Chalmeda Anand Rao Institute of Medical Sciences, Bommakal, Karimnagar, Telangana.
3Professor and HOD, Department of ENT, Chalmeda Anand Rao Institute of Medical Sciences, Bommakal, Karimnagar, Telangana.
4Associate Professor, Department of ENT, Chalmeda Anand Rao Institute of Medical Sciences, Bommakal, Karimnagar, Telangana.
5Postgraduate Resident, Department of ENT, Chalmeda Anand Rao Institute of Medical Sciences, Bommakal, Karimnagar, Telangana.
6Postgraduate Resident, Department of ENT, Chalmeda Anand Rao Institute of Medical Sciences, Bommakal, Karimnagar, Telangana.

ABSTRACT

BACKGROUND
The eye is especially susceptible to the symptoms of allergic rhinitis, itching (pruritus), tearing (epiphora) and redness (erythema) because it lacks a mechanical barrier that could prevent the deposition of allergens, such as pollen on the conjunctival surface. These ocular symptoms have been described as examples of the type 1 immediate hypersensitivity reaction. A number of recently published clinical studies apparently support the positive effect of intranasal steroidal sprays on ocular allergy symptoms.

The aim of the study is to evaluate the role of intranasal steroids in relieving ocular symptoms in allergic rhinitis.

MATERIALS AND METHODS
60 subjects who had seasonal allergic rhinitis with ocular symptoms came to Outpatient Department of Chalmeda Anand Rao Hospital in the year 2015-2016. Randomly, each intranasal steroid is given to 12 patients to a total of 60 patients for 4 weeks 2 puffs in each nostril twice daily and the clinical response is observed.

RESULTS
A subjective improvement in ocular symptoms was observed in 11 of the 12 patients treated with fluticasone furoate, 8 of 12 patients with fluticasone propionate, 7 of the 12 patients with mometasone furoate, 6 of the 12 patients with beclomethasone and 6 of the 12 patients with budesonide.

CONCLUSION
Intranasal corticosteroids, which are used for seasonal allergic rhinitis with ocular symptoms are effective in controlling ocular symptoms. Among these, intranasal corticosteroids, which are used for allergic rhinitis, fluticasone furoate is more effective in relieving ocular symptoms in our study.

KEYWORDS


BACKGROUND
Allergic rhinitis is a common disease affecting about 20% of the American population1 and is ranked as the fifth most costly chronic disease in the United States.2 Allergic rhinitis greatly affects patients' quality of life, cognitive and learning functions, decision-making and self-perception.3 Quality of life impairments related to allergic rhinitis also lead to decreased work productivity and classroom activity. Therefore, cost-effective treatment for the disease is important for both patient and society. Clinical symptoms of allergic rhinitis include sneezing, rhinorrhea, nasal itching and nasal congestion. According to an analysis of National Health and Nutrition Examination Survey III data, more than 40% of the US population with allergic rhinitis experienced ocular symptoms primarily manifesting as itchy and watery eyes regardless of age or geographic location.
In a study performed by Wuthrich et al, the authors evaluated 509 symptomatic patients with hay fever who were not currently receiving medical treatment and found that conjunctivitis symptoms were at least as severe as rhinitis symptoms in approximately 70% of the patients. Several reports also support substantial increases in the prevalence of Allergic Rhinocconjunctivitis (AR) in developed countries in recent decades making it an important health problem. A survey of 2500 United States symptomatic and/or treated AR patients found that 40% of responders complained of frequent watery eyes during allergy season.

Ocular symptoms can occur without evidence of direct conjunctival exposure to allergen. Lebel et al found that ocular symptoms were reported by approximately 20% of SAR patients in whom allergen provocation was isolated to the nasal mucosa. In a more recent study by Baroody et al, unilateral nasal provocation with ragweed or grass pollen resulted in ocular symptoms (itching and watery eyes) and increased ocular secretions bilaterally in SAR patients. Histamine and albumin in ocular secretions were not elevated, which indicates an absence of mast cell degranulation in the eye. In nasal secretions, biologic markers associated with an allergic response (histamine and albumin) were noted only on the side that was challenged, whereas the weight of nasal secretions increased bilaterally, because no nerves are known to communicate from one side of the nose to the other.

In a pooled, retrospective analysis of data from 7 randomised, double-blind trials (N=1645) that compared the efficacy of fluticasone propionate and placebo in SAR patients, fluticasone propionate was found to be significantly more effective than placebo in reducing baseline Total Ocular Symptom Score (TOSS) after 1 and 2 weeks of treatment.

Retrospective analyses assessed ocular symptom data from subjects with SAR who were randomised to receive mometasone furoate or placebo as part of 4 phase III, double-blind trials. Subjects who entered the studies were not required to have ocular symptoms at baseline and despite the low baseline TOSS and thus low potential for improvement, significantly greater improvement in TOSS was found with mometasone furoate vs. placebo over the 2-week treatment period.

Pooled analyses of data from the 4 phase III trials also showed significantly greater reductions in the 3 TOSS component symptoms (itching, redness and tearing) as well as in TOSS across all degrees of symptom severities at baseline. Benefit was seen as early as day 2, reaching statistical significance at day 3 and was sustained throughout the dosing interval. Recently published data indicate that fluticasone furoate is also more effective than placebo in reducing ocular symptoms associated with SAR. In a 2-week, dose-ranging study of fluticasone furoate (55 mcg, 110 mcg, 220 mcg and 440 mcg, all once daily) in patients with SAR, mean change in reflective TOSS and Rhinocconjunctivitis Quality of Life Questionnaire (RQLQ) eye symptom domain score were significantly greater in all active treatment groups compared with placebo. Comparison of once daily intranasal fluticasone furoate with placebo in subjects with SAR who had moderate-to-severe TOSS at baseline concluded that mean reductions from baseline were significantly greater with fluticasone furoate than with placebo for TOSS and each of the ocular symptoms.

A limited number of studies that compared the effectiveness of different INSs in reducing ocular symptoms in AR patients have been published. In addition to the previously discussed trial comparing budesonide, fluticasone propionate and placebo once daily mometasone furoate (200 mcg) was compared to twice daily beclomethasone dipropionate (200 mcg) over a 1 month treatment period. Mometasone furoate and beclomethasone dipropionate were superior to placebo in reducing total nasal and non-nasal symptom scores, which included itching, tearing and redness of the eyes and itching of the ears or palate. No statistically significant differences between the 2 active treatment groups were noted. Triamcinolone acetonide and fluticasone propionate, both once daily were compared over a 3-week treatment period in SAR patients. In the ocular outcome variable that was assessed in this study (the eye symptom domain of RQLQ), triamcinolone acetonide and fluticasone propionate were both superior to placebo and were not significantly different from each other.

OBJECTIVES
To determine the effectiveness of intranasal corticosteroids in controlling ocular symptoms of seasonal allergic rhinitis. To compare the effectiveness among the used individual intranasal steroids in overall improvement of ocular symptoms of seasonal allergic rhinitis.

MATERIALS AND METHODS
Type of Study- Observational comparative study.

Source of Data- 60 subjects who had seasonal allergic rhinitis with ocular symptoms came to Outpatient Department of Chalmeda Anand Rao Hospital in the year June 2015 to May 2016, informed consent from patients and approval has been obtained from the ethical committee of our institute. Intranasal corticosteroids used were beclomethasone dipropionate, budesonide, fluticasone furoate, fluticasone propionate and mometasone furoate.

Inclusion Criteria
Patients included both males and females with mild-to-severe seasonal allergic rhinitis with ocular symptoms. Age group of 10 to 60 years were included (Table 1).

Exclusion Criteria
Allergic rhinitis without eye symptoms, hypertension and diabetes mellitus.

Age group of more than 60 years and less than 10 years were not included.

Study duration was one year. Randomly, each intranasal steroid is given to 12 patients to a total of 60 patients for 6 weeks 2 puffs twice daily in each nostril. After 6 weeks of treatment with used different intranasal steroid sprays, we assessed the overall improvement in ocular symptoms by total ocular symptom score. Sum of the 3 individual ocular
symptoms (itching, watering and redness) was calculated on 0 to 3 grading (0=absent, 1=mild, 2=moderate, 3=severe). We hypothesised that repeated nasal allergen challenges would lead to priming and augmentation of nasonasal and nasal-ocular reflexes and that intranasal steroids would decrease inflammation and subsequently inhibit both nasonasal and nasal-ocular reflexes thus resulting in reduction of eye symptoms. Subjects recorded their nasal and ocular symptoms.

RESULTS
An overall clinical improvement in ocular symptoms was seen in 38 patients out of 60 of which pretreatment with beclomethasone dipropionate showed improvement in 6 patients (50%), budesonide in 6 patients (50%), fluticasone propionate in 8 patients (66.6%), mometasone furoate in 7 patients (58.3%) nasal spray reduced sneezing, the nasonasal and nasal-ocular reflexes (Figure 1). All the used intranasal steroids showed the positive results in improving the ocular symptoms, but it is more effective with fluticasone furoate, which showed a subjective improvement in 11 patients out of 12 (91.6%) (Table 2). The results of this study helped to confirm the existence of a nasal-ocular reflex after allergen challenge of the nose and demonstrated the exaggeration or priming of this reflex by repeated exposure to allergen and thus supported the role of the nasal-ocular reflex in the genesis of at least part of the eye symptoms in patients with AR. This study also helped to demonstrate the efficacy of fluticasone furoate over other intranasal steroids in reducing allergic inflammation, priming and subsequently the nasal-ocular reflex and ocular symptoms. Our results therefore support a mechanism that helps explain how control of eye symptoms can be achieved by the administration of fluticasone furoate in patients with seasonal allergic rhinitis.9

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-20 years</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>21-30 years</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>31-40 years</td>
<td>12</td>
<td>9</td>
</tr>
<tr>
<td>41-50 years</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>51-60 years</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**Table 1. Showing Age and Sex Distribution**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Number of Patients</th>
<th>Improvement in Ocular Symptoms</th>
<th>Percentage of Improved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluticasone furoate</td>
<td>12</td>
<td>11</td>
<td>91.6%</td>
</tr>
<tr>
<td>Fluticasone propionate</td>
<td>12</td>
<td>8</td>
<td>66.6%</td>
</tr>
<tr>
<td>Mometasone furoate</td>
<td>12</td>
<td>7</td>
<td>58.3%</td>
</tr>
<tr>
<td>Beclomethasone dipropionate</td>
<td>12</td>
<td>6</td>
<td>50%</td>
</tr>
<tr>
<td>Budesonide</td>
<td>12</td>
<td>6</td>
<td>50%</td>
</tr>
</tbody>
</table>

**Table 2. Showing Drugs Used and Percentage of Patients Improvement in Ocular Symptoms**

DISCUSSION
Intranasal Corticosteroids vs. Oral Antihistamines
Although, INSs are considered first-line therapy for moderate-to-severe AR, because they are especially effective for nasal congestion, non-sedating antihistamines have been recommended over INSs for relief of ocular symptoms. Contrary to expert opinion, a meta-analysis by Weiner et al of 16 randomised, controlled trials conducted between 1966 and 1997 found that oral antihistamines are not superior to INSs for the relief of ocular symptoms. Subsequent to the meta-analysis, loratadine was compared to both fluticasone propionate and triamcinolone in 28-day, randomised, controlled trials for SAR. Treatment with fluticasone propionate was associated with significantly greater reductions in TOSS and individual ocular symptoms compared with loratadine. The percentage of patients who reported relief from ocular symptoms was also higher with triamcinolone than with loratadine, although these differences only became significant in weeks 3 and 4.

Intranasal Corticosteroids vs. Topical Antihistamines
Topical ocular antihistamines are noted for their rapid onset of action and are associated with lower rates of sedation and dry eye than first generation oral antihistamines. There is a perception among physicians that non-sedating oral antihistamines maybe preferable to treat coexisting nasal symptoms present in the majority of SAC and PAC patients. A study by Abelson et al (N=500) demonstrated significant relief of sneezing, itchy nose and runny nose with olopatadine 0.2% vs. placebo (P=0.05). However, a meta-analysis of findings from 4 published clinical trials that compared the effects of INSs to topical (ocular) antihistamines on ocular symptoms in AR demonstrated no overall significant difference between the two treatment modalities. Fluticasone furoate was associated with significant improvement in TOSS and each of the individual symptoms.10 Mometasone furoate nasal spray and fluticasone furoate seem to have a relatively early onset of effect within 24 to 72 hours of initiation with a statistically significant mean change from baseline during the 15 days of the studies. The pooled analysis of the studies with mometasone furoate nasal spray found that improvements for individual symptoms occurred as early as day 2 of treatment.

In a study11 of budesonide in a paediatric population with perennial AR, eye symptom scores related to allergic conjunctivitis significantly decreased after 1 year of
treatment. Older studies with triamcinolone acetonide, budesonide and beclomethasone dipropionate provide further support of the positive effect of INSs in managing ocular allergy symptoms. Most of the published triamcinolone acetonide studies with ocular data are comparisons with an antihistamine (loratadine or astemizole). In 3 separate studies, triamcinolone acetonide was significantly more effective than or comparably effective with the antihistamine in reducing ocular symptoms as was reported in the meta-analysis of Weiner et al in other publications.12

Similar evidence of a positive effect of INSs on ocular allergy symptoms associated with seasonal AR can be found as far back as 1985 with beclomethasone dipropionate,13 although this early study did not find a significant improvement with the INS compared with an antihistamine. In a more recent study of patients with allergic or non-allergic chronic rhinosinusitis, Giger et al14 compared once daily with twice daily use of beclomethasone dipropionate and found a significant improvement for both groups in ocular tearing, itching and redness and in blepharoedema.

Several mechanisms of action have been proposed to explain the effect of INSs in reducing ocular symptoms related to AR. These possibilities include the following: (1) Improved drainage of the nasolacrimal duct related to the anti-inflammatory action of the INSs reduces exposure of the conjunctiva to allergens, (2) Application of the steroid to the eye through either systemic absorption or nasolacrimal reflux, (3) Reduced nasal inflammation moderates the allergic caused increases in reflex neuronal activity and (4) The systemic immune effect as reflected by the decreased immune profile found in the lung when the upper airway is treated perhaps a further extension of the one airway, one disease concept.

CONCLUSION
Most of the patients with allergic rhinitis have one or more ocular symptoms such as itching in eyes, watering from eyes and/or redness of eyes. When eye symptoms are associated with seasonal allergic rhinitis, these patients bother more about eye symptoms. All intranasal corticosteroid sprays are effective in controlling the eye symptoms in seasonal allergic rhinitis patients, but all are not equally effective. We conducted an observational study to know, which intranasal corticosteroid is more effective in controlling eye symptoms. We conclude that fluticasone furoate is more effective than other intranasal steroidal sprays.

REFERENCES